drughunter.com
13 minute read
Jul. 1, 2024

Drug Hunter 2023 M&A Review: Part 3 – Small Molecule-Focused Deals 10-1

Author:  
Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other articles you may be interested in

NaV1.7 Inhibitor Roundup: From Broad-Spectrum to Subtype-Selective Clinical Candidates

The discovery that individuals with null mutations in the NaV1.7 exhibited pain insensitivity sparked interest in targeting NaV1.7 to potentially treat pain. Despite the potential of selectively inhibiting sodium channels like NaV1.7, NaV1.8, and NaV1.9 for pain management, developing selective inhibitors suitable for clinical use has proven challenging. This article complements our coverage of VX-548, NaV1.8 as a critical target in pain management, and our NaV1.8 compound roundup and provides a reminder of noteworthy preclinical and clinical NaV1.7 small molecule inhibitors as of April 2024.

Drug Hunter 2023 M&A Review: Part 1 - Industry Overview

Drug Hunter has sifted through news articles, press releases, financial disclosures, SEC filings and more to bring you a roundup of 2023's biggest mergers and acquisitions (M&A) in the drug discovery world. In this 4-part series we will give you an open-access overview of the M&A landscape, and then for Drug Hunter members in the coming weeks, we will be providing in-depth coverage and analysis of the small molecule-focused (parts 2 & 3) and biologics-based deals (part 4). This premium content includes background on the targets, chemical/biological matter and clinical data driving these deals.

August Deals and Funding Rounds Recap

In case you missed August’s business news, here’s a quick recap of five headlines, including an acquisition, three funding rounds, and a notable company closure.

Billion-Dollar Molecules: M4 Modulators, GLP-1 Biased Agonists, and an SSTR2 Radiotherapy

Last December, the pharmaceutical industry witnessed many important updates for clinical molecules, ranging from neurology-based therapies to anti-tumors and radiopharmaceuticals, in addition to the unfortunate discontinuations. In case you missed it, here is a recap of the most notable news updates in the pharma world for December 2023

How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments | Flash Talk Highlights

Peptidic GLP-1R agonists have received significant media coverage over the past year for their astounding efficacy in several indications. While most of the recent fanfare has been related to their role in weight loss, GLP-1R agonists have been a mainstay of the type 2 diabetes treatment landscape for the past 2 decades. GLP-1R agonists have also recently shown efficacy in reducing heart disease risk and treating certain chronic kidney diseases. Here’s a recap of the March 14th, 2024, Flash Talk, from Oliver Philps.